Related Experiment Video

Updated: Jan 4, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

351

The multifaceted role of CARD9 in inflammatory bowel disease

Ping Luo1, Zhiwen Yang2, Bin Chen3

  • 1Department of Breast Surgery, Nanchang Third Hospital, Nanchang, China.

Journal of Cellular and Molecular Medicine
|November 8, 2019
PubMed

Insights

Caspase recruitment domain-containing protein 9 (CARD9) dysfunction is implicated in inflammatory bowel disease (IBD) pathogenesis. This review explores CARD9

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Inflammatory bowel disease (IBD) is characterized by an aberrant immune response to gut microbiota.
  • Caspase recruitment domain-containing protein 9 (CARD9) is increasingly recognized for its role in IBD pathogenesis.
  • Card9 variants exhibit dual roles, with common variants predisposing to and rare variants protecting against IBD.

Purpose of the Study:

  • To elucidate the mechanistic role of the CARD9 adaptor protein in the context of intestinal inflammation.
  • To explore the potential of targeting CARD9 as a therapeutic strategy for IBD.

Main Methods:

  • This review synthesizes existing research on CARD9 function in intestinal immunity.
  • Mechanistic insights are derived from studies investigating CARD9 signaling pathways.
  • The review analyzes genetic data linking Card9 variants to IBD susceptibility and protection.

Main Results:

  • CARD9 plays a critical role in regulating immune responses within the gut.
  • Dysfunctional CARD9 signaling contributes to the development and progression of IBD.
  • Specific Card9 variants influence IBD risk, highlighting its complex role.

Conclusions:

  • CARD9 is a key mediator of intestinal inflammation in IBD.
  • Targeting CARD9 presents a promising therapeutic avenue for managing IBD.
  • Further research into CARD9's precise functions could lead to novel IBD treatments.

Keywords:
CARD9inflammatory bowel diseasepredisposing and protective variantstherapy

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.5K
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

4.4K

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
890
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
820
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
416
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
589
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
417
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
432